StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a report issued on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock. VTVT has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on shares of vTv Therapeutics in a research note on Friday, […]
StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a report issued on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Cantor Fitzgerald began coverage on vTv Therapeutics in a research note on Friday, February 18th. They issued an overweight rating and a $5.00 price […]
vTv Therapeutics (NASDAQ:VTVT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 17.19% […]
/PRNewswire/ vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an.
StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock. Separately, Cantor Fitzgerald assumed coverage on shares of vTv Therapeutics in a research note on Friday, February 18th. They set an “overweight” rating […]